Premium
Nephrogenic systemic fibrosis versus contrast‐induced nephropathy: Risks and benefits of contrast‐enhanced MR and CT in renally impaired patients
Author(s) -
Martin Diego R.,
Semelka Richard C.,
Chapman Arlene,
Peters Harm,
Finn Paul J.,
Kalb Bobby,
Thomsen Henrik
Publication year - 2009
Publication title -
journal of magnetic resonance imaging
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.563
H-Index - 160
eISSN - 1522-2586
pISSN - 1053-1807
DOI - 10.1002/jmri.21968
Subject(s) - nephrogenic systemic fibrosis , medicine , contrast induced nephropathy , contrast (vision) , fibrosis , nephropathy , radiology , magnetic resonance imaging , endocrinology , computer science , artificial intelligence , diabetes mellitus
Magnetic resonance imaging (MRI) and computed tomography (CT) have become essential to diagnostic evaluation of many, or most, important medically and surgically treated diseases. It is important to consider comprehensively the implications in making decisions when choosing one or the other cross‐sectional imaging modality. Factors to consider include the relative risks of the contrast agent. Other factors include the relative procedural risks, including radiation risks and the relative expected diagnostic yield of the examination technique (1, 2). In this review we describe both nephrogenic systemic fibrosis and contrast‐induced nephropathy to compare the implications with regard to relative risks and benefits of contrast‐enhanced MRI or CT in patients with impaired renal function. J. Magn. Reson. Imaging 2009;30:1350–1356. © 2009 Wiley‐Liss, Inc.